More FDA inspection problems plague Impax
This article was originally published in Scrip
Impax Laboratories has been struggling lately with problems at its manufacturing facilities, with the latest involving a re-inspection by the FDA that turned up at least seven issues of concern at the company's Hayward, California plant, two of which were "repeat observations."
You may also be interested in...
Impax will gain 15 approved generics and three pipeline assets, which will help address offset lower revenues of two of its existing top-sellers.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.